Evidence map›Paper›PMID 35360724›Full record

ArticleFrontiers in medicine2022

Case Report: Challenges in the Diagnosis of a Case of Mal de Meleda and a Therapeutic Attempt of Ixekizumab and Adalimumab.

Yuwei Dai, Xiaodong Zheng, Qi Zhang, Xia Hu, Peiguang Wang, Sen Yang

Erratum issuedOpen access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Yuwei DaiDepartment of Dermatology, The First Affiliated Hospital, Anhui Medical University, Hefei, China.
Xiaodong ZhengDepartment of Dermatology, The First Affiliated Hospital, Anhui Medical University, Hefei, China.
Qi ZhangDepartment of Dermatology, The First Affiliated Hospital, Anhui Medical University, Hefei, China.
Xia HuDepartment of Dermatology, The First Affiliated Hospital, Anhui Medical University, Hefei, China.
Peiguang WangDepartment of Dermatology, The First Affiliated Hospital, Anhui Medical University, Hefei, China.
Sen YangDepartment of Dermatology, The First Affiliated Hospital, Anhui Medical University, Hefei, China.
Ministry of Education of the People's Republic of China · CNFirst Affiliated Hospital of Anhui Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Mal de Meleda (MDM, OMIM 248300) is an autosomal recessive disease characterized by symmetrical and progressive palmoplantar hyperkeratosis soon after birth. Mutations in Objective and Methods: A patient with suspected MDM was confirmed by the combination of next-generation sequencing and Exomiser, and the patient was attempted with the treatment of Ixekizumab and Adalimumab. Results: A homozygous mutation c.256G>A (p.Gly86Arg) in the Conclusions: Our findings helps to enhance the understanding of MDM. Ixekizumab may be a potential strategy to treat MDM.

Indexed as

AdalimumabExomiserHPO termsIxekizumabMal de MeledaMDM

Identifiers

PMID35360724
PMCPMC8961326
OpenAlexW4221102142

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.